International: +1-347-960-6455
Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

According to a new research report Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, MRSA therapeutics currently exhibits a proliferating pipeline with 20+ therapeutic candidates.

MRSA Therapeutics Pipeline Insights

Methicillin-resistant Staphylococcus aureus (MRSA) is an infection caused by Staphylococcus staph) bacteria, which are resistant to several antibiotics. The staph bacteria are naturally present in nose and on skin, but do not cause any harm. However, their uncontrolled multiplication leads to the onset of MRSA infection. Symptoms of MRSA infection depends on the area affected, ranging from mild to severe. Some of the commonly occurring symptoms include infection in bloodstream, surgical wounds, lungs, or urinary tract. Whereas, invasive medical devices, participating in sports requiring contact, living in crowded and non-sanitized surroundings, using intravenous drugs are some significant risk factors of the disease. The MRSA infection is caused by garden variety of Staphylococcus aureus, which is able to sustain in human body.

Moreover, the infection is contagious and are of two types: healthcare- associated MRSA (HA-MRSA), which is acquired from hospital or healthcare settings, often passed on through surgeries, artificial joints, and intravenous tubing; and community-associated MRSA (CA-MRSA), which is associated with infections transmitted through close personal contact with an affected person or through direct contact with an infected wound. CA-MRSA can start as painful boils.

Zyvox (Pfizer Inc.), Bactroban (GlaxoSmithKline plc), Baxdela (Melinta Therapeutics Inc.), and Teflaro (Allergan plc) are some of the U.S. Food and Drug Administration (USFDA) approved drugs, for the treatment of MRSA.

Insights into Pipeline Segments

According to the research, many drugs being developed for MRSA infection are administered intravenously. The advantage of this is that the entire administered dose reaches the systemic circulation immediately, which increases the bioavailability of drug. Administration of therapeutics for MRSA through intravenous route has shown promising results in clinical studies.

Positive Clinical Trial Results are Expected to Drive MRSA Therapeutics Pipeline

Companies that are involved in developing therapeutics for MRSA have shown positive clinical results in various phases of drug development. For instance, in 2018, Melinta Therapeutics Inc. announced positive topline results of phase III trial of Baxdela for community-acquired bacterial pneumonia (CABP) and was found to cure MRSA also. Baxdela also met the FDA secondary endpoint of statistical non-inferiority (90.5%) compared to moxifloxacin (89.7%) based on investigator’s assessment of success at the test-of-cure visit (5–10 days after last dose) in the intent-to-treat population (ITT) population.

Technological Advancements Play a Pivotal Role in MRSA Therapeutics Development

It has been observed that many pharmaceutical companies are developing new and improved technologies for the development of MRSA therapeutics. These technologies play an important role in the drug development by helping the companies to develop more specific and effective targeted therapies. For instance, Crystal Genomics Inc. is developing CG400549 using its proprietary technology, structural-based drug factory (SDF), which optimizes novel leads to drug candidate compounds using 3D structure information of the complexes of target proteins and inhibitors.

Browse report overview with detailed TOC on "Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments" at:

Global Market for MRSA Therapeutics is Expected to Increase Statistically in the Next 10 years

As of 2019, there are four marketed drugs for MRSA, such as Zyvox, Bactroban, Baxdela, and Teflaro. With the sale of these drugs and the emergence of products in pipeline project, the market for MRSA therapeutics is expected to witness significant growth in the coming years.

GlaxoSmithKline plc, Pfizer Inc., Crystal Genomics Inc., Melinta Therapeutics Inc., Allergan plc, The Medicines Company, and Innovation Pharmaceuticals Inc. are some of the prominent players for development of MRSA therapeutics.

MRSA Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of MRSA. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the MRSA therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to MRSA.